Lifileucel(自体肿瘤浸润淋巴细胞单一疗法)用于免疫检查点抑制剂耐药的晚期非小细胞肺癌患者
这项2期多中心研究评估了lifileucel(LN-145)在既往接受过免疫治疗且最近一次治疗进展的转移性非小细胞肺癌(mNSCLC)患者中的疗效与安全性。既往系统治疗中位数为2线(范围1-6)。客观缓解率为21.4%(6/28)。缓解见于通常对免疫治疗耐药的肿瘤特征,如PD-L1阴性、低肿瘤突变负荷和STK11突变。两名患者死于治疗中出现的不良事件:心力衰竭和多器官衰竭。
要点
- 客观缓解率为21.4%(6/28),缓解见于PD-L1阴性、低肿瘤突变负荷和STK11突变等通常对免疫治疗耐药的肿瘤。
- 两例缓解在数据截止时仍在持续,包括一例PD-L1阴性肿瘤的完全代谢缓解。
- 两名患者死于治疗中出现的不良事件:心力衰竭和多器官衰竭。
核心结论
- Lifileucel是既往治疗难治的转移性非小细胞肺癌患者的一种潜在治疗选择。
研究设计与样本
- 这项2期多中心研究评估了lifileucel(LN-145)在既往接受过免疫治疗且最近一次治疗进展的转移性非小细胞肺癌患者中的疗效与安全性。
- 既往系统治疗中位数为2线(范围1-6)。
- Lifileucel使用来自不同解剖部位(以肺为主)的肿瘤组织成功制备。
主要发现
- 客观缓解率为21.4%(6/28)。
- 缓解见于通常对免疫治疗耐药的肿瘤特征,如PD-L1阴性、低肿瘤突变负荷和STK11突变。
- 两例缓解在数据截止时仍在持续,包括一例PD-L1阴性肿瘤的完全代谢缓解。
- 不良事件总体符合预期且可控。
- 两名患者死于治疗中出现的不良事件:心力衰竭和多器官衰竭。
临床怎么用
- 作者认为lifileucel是既往治疗难治的转移性非小细胞肺癌患者的一种潜在治疗选择。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this phase 2 multicenter study, we evaluated the efficacy and safety of lifileucel (LN-145), an autologous tumor-infiltrating lymphocyte cell therapy, in patients with metastatic non-small cell lung cancer (mNSCLC) who had received prior immunotherapy and progressed on their most recent therapy. The median number of prior systemic therapies was 2 (range, 1-6). Lifileucel was successfully manufactured using tumor tissue from different anatomic sites, predominantly lung. The objective response rate was 21.4% (6/28). Responses occurred in tumors with profiles typically resistant to immunotherapy, such as PD-L1-negative, low tumor mutational burden, and STK11 mutation. Two responses were ongoing at the time of data cutoff, including one complete metabolic response in a PD-L1-negative tumor. Adverse events were generally as expected and manageable. Two patients died of treatment-emergent adverse events: cardiac failure and multiple organ failure. Lifileucel is a potential treatment option for patients with mNSCLC refractory to prior therapy. Significance: Autologous tumor-infiltrating lymphocyte therapy lifileucel was administered to 28 patients with heavily pretreated metastatic non-small cell lung cancer (mNSCLC). Responses were observed in patients with driver mutations, and various tumor mutational burdens and PD-L1 expression, potentially addressing an unmet medical need in patients with mNSCLC refractory to prior therapy. See related commentary by Lotze et al., p. 1366.
引用
- Schoenfeld AJ, Lee SM, Doger de Spéville B, et al. Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors. Cancer Discov. 2024. PMID: 38563600. doi:10.1158/2159-8290.CD-23-1334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。